- Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14:9–32. doi:https://doi.org/10.20892/j.issn.2095-3941.2016.0084.
- Ebina Y, Uchiyama M, Imafuku H, Suzuki K, Miyahara Y, Yamada H. Risk factors for deep venous thrombosis in women with ovarian cancer. Medicine (Baltimore). 2018;97:e11009–e11009. doi:https://doi.org/10.1097/MD.0000000000011009.
- Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122:1712–1723. doi:https://doi.org/10.1182/blood-2013-04-460121.
- Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res. 2006;118:555–568. doi:https://doi.org/10.1016/j.thromres.2005.10.015.
- Higgins J, Thomas J. Cochrane Handbook for Systematic Reviews of Interventions version 6.0. Cochrane; 2019. https://training.cochrane.org/handbook/archive/v6. Accessed September 28, 2021.
- Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. doi:https://doi.org/10.1371/journal.pmed.1000097.
- Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560. doi:https://doi.org/10.1136/bmj.327.7414.557.
- Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366:601–609. doi:https://doi.org/10.1056/NEJMoa1108898.
- Khorana AA, Soff GA, Kakkar AK, et al; CASSINI Investigators. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380:720–728. doi:https://doi.org/10.1056/NEJMoa1814630.
- Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood. 1983;62:14–31. doi:https://doi.org/10.1182/blood.V62.1.14.14.
- Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846–1850. doi:https://doi.org/10.1056/NEJM200012213432504.
- Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78:285–291. doi:https://doi.org/10.1097/00005792-199909000-00001.
- Agnelli G, Gussoni G, Bianchini C, et al; PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10:943–949. doi:https://doi.org/10.1016/S1470-2045(09)70232-3.
- Farge D, Frere C, Connors JM, et al; International Initiative on Thrombosis and Cancer (ITAC) Advisory Panel. 2019 International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20:e566–e581. doi:https://doi.org/10.1016/S1470-2045(19)30336-5.
- Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38:496–520. doi:https://doi.org/10.1200/JCO.19.01461.
- Fleming ND, Dal Molin GZ, Fellman B, et al. Lack of utility of the Khorana score for predicting VTE in advanced ovarian cancer. Gynecol Oncol. 2020;159:111. doi:https://doi.org/10.1016/j.ygyno.2020.05.119.
- Marcus E, Kuo DY-S, Nevadunsky NS, Gressel GM. Association of the Khorana score with development of venous thromboembolism in ovarian cancer. JCO. 2021;39(suppl):5555. doi:https://doi.org/10.1200/JCO.2021.39.15_suppl.5555.
Meta-analysis of randomized controlled trials on primary ambulatory thromboprophylaxis in patients with ovarian cancer receiving chemotherapy
Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.